TY - JOUR
KW - Adult
KW - Buprenorphine/therapeutic use
KW - COVID-19
KW - Drug Overdose/epidemiology
KW - Humans
KW - insurance
KW - Opioid-Related Disorders/drug therapy/epidemiology
KW - Pandemics
KW - SARS-CoV-2
KW - United States
KW - buprenorphine
KW - disparities
KW - Medications for opioid use disorder
AU - J. Cantor
AU - A. W. Dick
AU - R. Haffajee
AU - M. F. Pera
AU - D. M. Bravata
AU - B. D. Stein
AU - C. M. Whaley
A1 - 
AD - RAND Corporation, Santa Monica, CA, United States of America. Electronic address: jcantor@rand.org.; RAND Corporation, Boston, MA, United States of America.; RAND Corporation, Boston, MA, United States of America; Department of Health Management & Policy, University of Michigan, United States of America.; Castlight Health, San Francisco, CA, United States of America.; Castlight Health, San Francisco, CA, United States of America; Center for Primary Care and Outcomes Research, Stanford, CA, United States of America.; RAND Corporation, Pittsburgh, PA, United States of America.; RAND Corporation, Santa Monica, CA, United States of America.
BT - Journal of substance abuse treatment
C5 - Financing & Sustainability; Healthcare Disparities; Opioids & Substance Use
DO - 10.1016/j.jsat.2021.108384
JF - Journal of substance abuse treatment
LA - eng
M1 - Journal Article
PB - Elsevier Inc
PY - 2021
SN - 1873-6483; 0740-5472; 0740-5472
SP - 108384
T1 - Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic
T2 - Journal of substance abuse treatment
TI - Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic
U1 - Financing & Sustainability; Healthcare Disparities; Opioids & Substance Use
U2 - 34080552
U3 - 10.1016/j.jsat.2021.108384
VL - 129
VO - 1873-6483; 0740-5472; 0740-5472
Y1 - 2021
Y2 - Oct
ER -